Furthermore, through inhibition of both the canonical and non-canonical NF-κB pathways, bortezomib interferes with the downstream signaling of BAFF and APRIL.41 This shows us that, although bortezomib targets multiple processes, at least a part of its anti-myeloma effect may be attributed to the inhibition of the BAFF/APRIL axis. The gene discussed is TNFSF13B; the disease is plasma cell myeloma.